ALNYLAM PHARMACEUTICALS, INC. CORPORATE GOVERNANCE GUIDELINES The Board of Directors (the “Board”) of Alnylam Pharmaceuticals, Inc. (the “Company”) has adopted the
Efter en hemsk 2016 efter förlusten av dess ledande läkemedelskandidat, Alnylam Pharmaceuticals. (NASDAQ: ALNY). har haft ett ganska bra år, upp 238%
For Investor Alnylam Pharmaceuticals Inc. Alnylam Pharmaceuticals, Inc. operates as biopharmaceutical company, which engages in the discovery, development and commercialization of RNAi therapeutics. Alnylam Pharmaceuticals, Inc. is a biopharmaceutical company. The Company is engaged in the discovery, development and commercialization of ribonucleic acid … Alnylam Pharmaceuticals Conference Call to Discuss Full 9-Month Results from the HELIOS-A Phase 3 Study of Vutrisiran Listen to Webcast › Apr 13, 2021 / 01:30 PM EDT 2021-02-05 Prior to Alnylam, Dr. Maraganore served as an officer and a member of the management team for Millennium Pharmaceuticals, Inc. As Senior Vice President, Strategic Product Development for Millennium, he was responsible for the company’s product franchises in oncology, and cardiovascular, inflammatory, and metabolic diseases. Alnylam Pharmaceuticals Inc at Piper Jaffray Health Care Conference: Nov 21, 2011 12:00 AM EST Nov 21, 2011 at 12:00 AM EST: Alnylam Pharmaceuticals Inc Conference Call to Discuss Phase I Results of ALN-TTR01 Clinical Trial 2020-08-13 Alnylam Pharmaceuticals Inc (NASDAQ: ALNY) has announced that trial results from the ILLUMINATE-A Phase 3 study evaluating lumasiran for the treatment of primary hyperoxaluria type 1 (PH1). With the business potentially at an important milestone, we thought we'd take a closer look at Alnylam Pharmaceuticals, Inc.'s (NASDAQ:ALNY) future prospects.
Alnylam has led the translation of RNAi (RNA interference) from Nobel Prize-winning discovery into an Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing, and commercializing RNA interference (RNAi) therapeutics. Stock Price Forecast. The 21 analysts offering 12-month price forecasts for Alnylam Pharmaceuticals Inc have a median target of 180.00, with a high estimate of Alnylam Pharmaceuticals, Inc. Alnylam provides RNAi therapeutics and expertise. Get started. Simply fill out the registration View today's stock price, news and analysis for Alnylam Pharmaceuticals Inc. ( ALNY).
Alnylam Pharmaceuticals, Inc (NASDAQ:ALNY) Q4 2020 Earnings Conference Call February 11, 2021 8:30 AM ET. Company Participants. Christine Lindenboom - Senior Vice President of Investor Relations
Alnylam Pharmaceuticals Inc är en aktie med Kupujte a prodávejte investiční nástroj Alnylam Pharmaceuticals Inc na eToro. Sledujte graf nástroje $ALNY a využívejte aktualizace v reálném Det fanns inte för många hetare biotekniska produkter år 2017 än Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY) .
11 rows
Healthcare. Pharmaceuticals & Medical Research The company is located in Huddinge, Sweden. Sales per ALNYLAM PHARMACEUTICALS, INC. 15.59 Källa, Alnylam Pharmaceuticals. Kort sammanfattning. This study will use specific diagnostic tests on a group of patients who are experiencing symptoms typical Det hände dock aktier G5 Löning och sparande Herantis Pharma aktier. Konvertera Alnylam Pharmaceuticals Inc () till Malaysian Ringgit Volymen av aktiehandeln Alnylam Pharmaceuticals, Inc. idag och historien om kapitaliseringen av Alnylam Pharmaceuticals, Inc. från början av handeln med Värdepapper: Alnylam Pharmaceuticals Inc. Valuta: USD. Valutakurs: 8.7528.
X . You are now leaving Alnylam.com.
Netent aktieägare
Alnylam to Webcast Presentations at Upcoming March Investor Conferences: Feb 18, 2021: Alnylam to Webcast Presentation at 10th Annual SVB Leerink Global Healthcare Conference: Feb 11, 2021: Alnylam Pharmaceuticals Reports Fourth Quarter and Full Year 2020 Financial Results and Highlights Recent Period Activity: Jan 28, 2021 Alnylam Pharmaceuticals does not endorse and is not responsible for the content on sites that are not owned and operated by Alnylam Pharmaceuticals. Proceed to Site. X .
The Investor Relations website contains information about Alnylam Pharmaceuticals, Inc.'s business for stockholders, potential investors, and financial analysts.
Lisebergsteatern minns du mig
Prior to Alnylam, Dr. Maraganore served as an officer and a member of the management team for Millennium Pharmaceuticals, Inc. As Senior Vice President, Strategic Product Development for Millennium, he was responsible for the company’s product franchises in oncology, and cardiovascular, inflammatory, and metabolic diseases.
The Investor Relations website contains information about Alnylam Pharmaceuticals, Inc.'s business for stockholders, potential investors, and financial analysts. Alnylam Pharmaceuticals Inc. Alnylam Pharmaceuticals, Inc. operates as biopharmaceutical company, which engages in the discovery, development and commercialization of RNAi therapeutics. Alnylam Assist® offers personalized, comprehensive support for patients throughout treatment with Alnylam products.